NCT07166757View on ClinicalTrials.gov

Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2029

Conditions
Parkinson Disease (PD)
Interventions
DRUG

human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

5.0×10\^7 cells/mL, injection, once, 12 months

All Listed Sponsors
lead

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

INDUSTRY